Expert to Present Data on CDI Patients at Risk of Recurrence and Mortality at SHEA Annual Meeting

Article

Optimer Pharmaceuticals, Inc. announces that data highlighting the burden of Clostridium difficile infection using national health insurance claims and survey databases will be presented on April 2, 2011 at the 21st annual scientific meeting of the Society for Healthcare Epidemiology of America (SHEA).

Erik R. Dubberke, MD, MSPH, of Washington University School of Medicine in St. Louis, will present the poster, "Rates of Recurrence and Mortality Among Patients with a Diagnosis of Clostridium Difficile Infection in the United States: An Analysis Using National Health Insurance Claims and Survey Databases on Saturday, April 2, 2011 from 1 p.m. to 2:15 p.m. CT in the Trinity Ballroom at the Hilton Anatole Hotel in Dallas.

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development.

Recent Videos
Pathogen Playbook Presenter: Sharon Ward-Fore, BS, MS, MT(ASCP), CIC, FAPIC
Mark Wiencek, PhD
Rebecca Crapanzano-Sigafoos, DrPH, CIC, AL-CIP, FAPIC
The CDC’s updated hospital respiratory reporting requirement has added new layers of responsibility for infection preventionists. Karen Jones, MPH, RN, CIC, FAPIC, clinical program manager at Wolters Kluwer, breaks down what it means and how IPs can adapt.
Studying for the CIC using a digital tablet and computer (Adobe Stock 335828989 by NIKCOA)
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Infection Control Today's Conversations with the HSPA President, Arlene Bush, CRCST, CER, CIS, SME, DSMD, CRMST
Cheron Rojo, BS, FCS, CHL,  CER, CFER, CRCST
Matthias Tschoerner, Dr Sc
Standardizing Cleaning and Disinfection
Related Content